Abstract

BackgroundAcute intermittent porphyria (AIP) is a genetic disease characterized by acute neurovisceral attacks. Long-term clinical conditions, chronic symptoms and impaired health related quality of life (HRQoL) have been reported during non-attack periods but mainly in patients with recurrent attacks. Our aim was to investigate these aspects in sporadic AIP (SA-AIP) and latent AIP (L-AIP) patients. Fifty-five participants, 27 SA-AIP (< 4 attacks/year) and 28 L-AIP patients with a prevalent founder mutation from Spain were included. Medical records were reviewed, and individual interviews, physical examinations, biochemical analyses, and abdominal ultrasound scans were conducted. HRQoL was assessed through an EQ-5D-5L questionnaire. A comparative study was made between SA-AIP and L-AIP patients.ResultsThe earliest long-term clinical condition associated with SA-AIP was chronic kidney disease. Chronic symptoms were reported in 85.2 % of SA-AIP and 46.4 % of L-AIP patients. Unspecific abdominal pain, fatigue, muscle pain and insomnia were significantly more frequent in SA-AIP than in L-AIP patients. The EQ-5D-5L index was lower in SA-AIP (0.809 vs. 0.926, p = 0.0497), and the impact of “pain”, “anxiety-depression” and “mobility” was more intense in the EQ-5D-5L domains in SA-AIP than in L-AIP subjects and the general Spanish population.ConclusionsAIP remains a chronically symptomatic disease that adversely affects health and quality of life, even in patients with low rate of acute attacks. We suggest a regular monitoring of patients with symptomatic AIP regardless of their attack rate or the time since their last attack, with proper pain management and careful attention to kidney function.

Highlights

  • Acute intermittent porphyria (AIP) is a genetic disease characterized by acute neurovisceral attacks

  • Of the 55 individuals included with confirmed hydroxymethylbilane synthase (HMBS) pathogenic variants, 80 % carried the founder mutation NM_000190.3: c.669_698del30 p.(Glu223_Leu232)

  • The findings show that long-term clinical conditions and chronic symptoms more frequently occur in sporadic AIP (SA-AIP) patients compared with latent AIP (L-AIP)

Read more

Summary

Introduction

Acute intermittent porphyria (AIP) is a genetic disease characterized by acute neurovisceral attacks. Long-term clinical conditions, chronic symptoms and impaired health related quality of life (HRQoL) have been reported during non-attack periods but mainly in patients with recurrent attacks. Fifty-five participants, SA-AIP (< 4 attacks/year) and L-AIP patients with a prevalent founder mutation from Spain were included. Most HMBS pathogenic variants are private, founder effects have been reported [2]. The clinical course of AIP is characterized by acute neurovisceral attacks involving the autonomic, peripheral and central nervous systems, with intervening non-attack periods [5, 6]. After recovery from a neurovisceral attack, the levels of urinary ALA (U-ALA) and U-PBG may remain high for long periods of time [7,8,9]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.